Lenz & Staehelin advises Asceneuron on its agreement with Ferrer

Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy (PSP), an orphan neurological disease with a high unmet medical need.

This agreement underscores the commitments both companies have undertaken to improve the lives of patients with a rare disease, such as Progressive Supranuclear Palsy (PSP). The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible to receive tiered double-digit royalties on worldwide net sales of ASN90.

Lenz & Staehelin advised Asceneuron in this transaction. The team was led by partner Sevan Antreasyan (IP, commercial and contracts, pictured) and included Anne-Laure Laplace (IP, commercial and contracts) and Federico Trabaldo Togna (corporate and m&a).

Lenz & Staehelin advises Asceneuron on its agreement with Ferrer



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram